← back to search

David Mischoulon

Lemuel Shattuck Hospital · NL
Area of research
Pharmacology · Biological Psychiatry
Research interest
Research interests include Treatment of Major Depression, Tryptophan and brain disorders, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, and Mental Health Treatment and Access.
h-index
71
citations
17,513
works
441
NIH funding
primary concept
email

Recent publications

Heated yoga thaws depression: A dose-response analysis from a randomized controlled trial.
2026cited by 0position: contributordoi
Ketamine-Assisted Psychotherapy for Treatment of an Asian American Patient with Post-Traumatic Stress Disorder (PTSD): A Case Study
Psychiatry Research Case Reports 2026cited by 0position: contributordoi
Moderating effects of stigma-related barriers on ethnic identity dimensions and mental health service utilization among Black adults in the US
International Journal of Intercultural Relations 2025cited by 0position: contributordoi
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
Neuropsychopharmacology 2023cited by 27position: middledoi
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial
Brain Behavior & Immunity - Health 2023cited by 12position: middledoi
A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
2023cited by 11position: contributordoi
Personalized Medicine of Omega-3 Fatty Acids in Depression Treatment in Obese and Metabolically Dysregulated Patients.
2023cited by 9position: contributordoi
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce
The World Journal of Biological Psychiatry 2022cited by 195position: middledoi
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
2022cited by 110position: contributordoi
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation
The Journal of Clinical Psychiatry 2022cited by 51position: firstdoi
Quantifying and addressing the impact of measurement error in network models
Behaviour Research and Therapy 2022cited by 38position: contributordoi
Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder
The Journal of Clinical Psychiatry 2022cited by 34position: middledoi
Four-Week Mentalizing Imagery Therapy for Family Dementia Caregivers: A Randomized Controlled Trial with Neural Circuit Changes
Psychotherapy and Psychosomatics 2022cited by 22position: contributordoi
How family dementia caregivers perceive benefits of a 4-week mentalizing imagery therapy program: A pilot study.
Professional Psychology: Research and Practice 2022cited by 8position: contributordoi
Depressed Chinese Americans present predominantly psychological symptoms: A new trend or different outcomes due to methodological differences?
Asian Journal of Psychiatry 2021cited by 6position: contributordoi
Diet and depression: exploring the biological mechanisms of action
Molecular Psychiatry 2020cited by 622position: middledoi
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
Prostaglandins Leukotrienes and Essential Fatty Acids 2020cited by 60position: middledoi
Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study
Psychological Medicine 2020cited by 16position: middledoi
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder
Psychotherapy and Psychosomatics 2019cited by 193position: middledoi
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
2019cited by 125position: contributordoi
Tachyphylaxis in major depressive disorder: A review of the current state of research
Journal of Affective Disorders 2018cited by 43position: middledoi
Prospective association between major depressive disorder and leukocyte telomere length over two years
Psychoneuroendocrinology 2018cited by 43position: middledoi
Circulating microRNAs as biomarkers for depression: Many candidates, few finalists
Journal of Affective Disorders 2017cited by 87position: middledoi
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD)
Brain stimulation 2017cited by 28position: middledoi
Effects of Mindfulness-Based Cognitive Therapy on Body Awareness in Patients with Chronic Pain and Comorbid Depression
Frontiers in Psychology 2016cited by 199position: middledoi
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
Molecular Psychiatry 2015cited by 264position: lastdoi
A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women
Evidence-based Complementary and Alternative Medicine 2015cited by 43position: lastdoi
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)
Psychotherapy and Psychosomatics 2012cited by 141position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Maurizio Fava · Massachusetts General Hospital11 papers (2012–2023) · 10 papers (2019–2026)Mark Hyman Rapaport · University of Utah6 papers (2015–2023)Pamela J. Schettler · Emory University6 papers (2015–2023)Boadie W. Dunlop · Emory University5 papers (2017–2023)Becky Kinkead · University of Utah5 papers (2015–2023)Stefania Lamon‐Fava · Tufts University4 papers (2020–2023)Andrew A. Nierenberg · St. Mary's University, Texas4 papers (2015–2022)Cristina Cusin · Harvard University4 papers (2017–2022)Thomas R. Ziegler · Emory University3 papers (2020–2023)Dan V. Iosifescu · Psychiatric Medical Center3 papers (2012–2022)Marlene P. Freeman · Harvard University3 papers (2017–2019)Jennifer C. Felger · Emory University3 papers (2020–2023) · 2 papers (2012–2017) · 2 papers (2022–2022)Megha Nagaswami · University of California, Los Angeles2 papers (2021–2026)Felipe A. Jain · SpringerNature2 papers (2022–2022)Kuan-Pin Su · Beijing Friendship Hospital2 papers (2019–2023) · 2 papers (2022–2022)Yian Wu · Massachusetts General Hospital2 papers (2026–2026)